PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
TL;DR
In R/M HNSCC, integrating IP with PD-L1 expression may enhance prediction of ICI outcomes and was an independent factor for PFS.
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Head and Neck Cancer Studies
Ferroptosis and cancer prognosis
In R/M HNSCC, integrating IP with PD-L1 expression may enhance prediction of ICI outcomes and was an independent factor for PFS.
- p-value P = .015
- p-value P = .018
APA
Dong Hyun Kim, Jiwon Koh, et al. (2026). PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.. Oral surgery, oral medicine, oral pathology and oral radiology, 141(5), 679-689. https://doi.org/10.1016/j.oooo.2025.11.018
MLA
Dong Hyun Kim, et al.. "PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.." Oral surgery, oral medicine, oral pathology and oral radiology, vol. 141, no. 5, 2026, pp. 679-689.
PMID
41486033
Abstract
[OBJECTIVE] Programmed cell death-ligand 1 (PD-L1) expression and immune phenotype (IP) are potential predictive biomarkers for immune checkpoint inhibitors (ICIs) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This study evaluated the predictive value of combining PD-L1 expression and IP in R/M HNSCC.
[STUDY DESIGN] Forty-one R/M HNSCC patients treated with ICI were included. PD-L1 expression was evaluated using the standardized 22C3 pharmDx assay. IPs were assessed using Lunit SCOPE IO, an artificial intelligence-powered tumor-infiltrating lymphocyte analyzer.
[RESULTS] Thirty-nine patients (95.1%) were classified as PD-L1 positive (combined positive score ≥1). Overall, 27 (65.9%) had desert IP. PD-L1 expression and IP were combined to classify patients into 3 groups: group A, negative PD-L1; group B, positive PD-L1 with desert IP; group C, positive PD-L1 with non-desert IP. The median progression-free survival (PFS) was 1.2 months in group A, 2.1 months in group B, and 12.1 months in group C (P = .015). In multivariate Cox analysis, PD-L1 expression combined with IP was an independent factor for PFS, with a hazard ratio of 0.14 (P = .018) in group C and 0.37 (P = .186) in group B, relative to group A.
[CONCLUSIONS] In R/M HNSCC, integrating IP with PD-L1 expression may enhance prediction of ICI outcomes.
[STUDY DESIGN] Forty-one R/M HNSCC patients treated with ICI were included. PD-L1 expression was evaluated using the standardized 22C3 pharmDx assay. IPs were assessed using Lunit SCOPE IO, an artificial intelligence-powered tumor-infiltrating lymphocyte analyzer.
[RESULTS] Thirty-nine patients (95.1%) were classified as PD-L1 positive (combined positive score ≥1). Overall, 27 (65.9%) had desert IP. PD-L1 expression and IP were combined to classify patients into 3 groups: group A, negative PD-L1; group B, positive PD-L1 with desert IP; group C, positive PD-L1 with non-desert IP. The median progression-free survival (PFS) was 1.2 months in group A, 2.1 months in group B, and 12.1 months in group C (P = .015). In multivariate Cox analysis, PD-L1 expression combined with IP was an independent factor for PFS, with a hazard ratio of 0.14 (P = .018) in group C and 0.37 (P = .186) in group B, relative to group A.
[CONCLUSIONS] In R/M HNSCC, integrating IP with PD-L1 expression may enhance prediction of ICI outcomes.
MeSH Terms
Humans; B7-H1 Antigen; Male; Female; Middle Aged; Immune Checkpoint Inhibitors; Squamous Cell Carcinoma of Head and Neck; Aged; Neoplasm Recurrence, Local; Biomarkers, Tumor; Head and Neck Neoplasms; Phenotype; Adult; Treatment Outcome; Prognosis; Retrospective Studies; Aged, 80 and over; Neoplasm Metastasis; Predictive Value of Tests
같은 제1저자의 인용 많은 논문 (5)
- A Case Report of Systemic Intoxication Following Onabotulinum Toxin A Injections Into the Salivary Glands in a Patient With Spinal Muscular Atrophy Type 1.
- CT Colonography for Colorectal Cancer Prevention and Detection: Integration Into Clinical Practice, From the Special Series on Screening.
- Tumor Exosomal L1 Cell Adhesion Molecule Promotes Brain Metastasis of Lung Cancer.
- Response to Letter Regarding "Herbal Medicine Combined With Chemotherapy in Advanced NSCLC".
- Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.